Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
    • CME
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Breast Cancer
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Clinical Cancer Research
Clinical Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
    • CME
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Breast Cancer
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Advances in Brief

p14ARF Promoter Hypermethylation in Plasma DNA as an Indicator of Disease Recurrence in Bladder Cancer Patients

Gemma Domínguez, Joaquín Carballido, Javier Silva, Jose M. Silva, Jose M. García, Josefa Menéndez, Mariano Provencio, Pilar España and Felix Bonilla
Gemma Domínguez
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joaquín Carballido
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Javier Silva
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jose M. Silva
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jose M. García
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Josefa Menéndez
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mariano Provencio
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pilar España
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Felix Bonilla
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published April 2002
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Purpose: Several genes are reported to be implicated in bladder carcinogenesis, including p53, p16INK4a, pRb, erbB-2, Cyclin D1, H-ras, EGFR, and c-myc. Gene alterations in plasma DNA identical to those observed within the tumor have been detected in various types of neoplasia.

Experimental Design: We analyzed loss of heterozygosity in six microsatellite markers (D17S695, D17S654, D13S310, TH2, D9S747, and D9S161), p53 and K-ras mutations, and the promoter status of p14ARF and p16INK4a in the mononuclear normal blood cells, tumor, and plasma DNA of 27 bladder cancer patients. We also studied the distribution of several clinicopathological parameters in these patients in regard to molecular alterations.

Results: Seventeen (63%) cases displayed the same alteration in plasma and tumor DNA (some patients showed more than one alteration simultaneously). Plasma p14ARF promoter hypermethylation was associated with the presence of multicentric foci (P = 0.03), larger tumors (P = 0.01), and relapse of the disease (P = 0.03). Plasma loss of heterozygosity was also linked to disease recurrence (P = 0.02).

Conclusions: The results indicate that p14ARF aberrant promoter methylation could be involved in bladder carcinogenesis and that plasma DNA is a potential prognostic marker in urinary bladder cancer.

Introduction

Urinary bladder cancer is the fifth most common tumor in Western societies. Its occurrence increases with age and it is greater in men (with a sex ratio between 3:1 and 4:1; Ref. 1 ). The risk of bladder cancer is doubled in smokers (2) , but there are other risk factors (3) . About 95% of bladder neoplasms are transitional cell carcinomas. The remainder are squamous tumors, adenocarcinomas, and other subtypes. At the time of diagnosis, >60% of the transitional carcinomas are papillary noninvasive (Ta), 10–20% show invasion limited to the lamina propria (T1), and 20% present muscle or deeper infiltration (T2-T4; Refs. 4 , 5 ). Between 15 and 30% of bladder tumors show grade and stage progression (3 , 6) . Despite radical local therapy, half the patients with muscle-invasive bladder tumors die from metastatic disease (7) . Bladder cancer is the result of monoclonal genetic changes, and the multiple synchronous or metachronous tumors are derived from micrometastatic foci that have migrated from the original site rather than from a polyclonal mutation (8, 9, 10) .

Many studies have sought predictive markers in bladder cancer patients. Several genes are involved, including erbB-2, EGFR, c-myc, Cyclin D1, H-ras, p53, p16INK4a, and pRb. Frequent deletions at 2q, 3p, 4q, 5q, 6q, 8p, 9p, 9q, 11p, 11q, and 13q, and frequent gains of 1q, 3q, 5p, 6p, chromosome 7, 8q, 17q, and 20q may pinpoint the location of other, yet unidentified tumor suppressor genes and oncogenes with a role in bladder cancer (11, 12, 13, 14, 15) .

Free-circulating tumor DNA has been detected in peripheral blood of both healthy subjects and tumor patients. The mean concentration of soluble DNA in plasma was 14 ng/ml in control subjects (16) and 180 ng/ml in cancer patients (17) . Gene alterations identical to those observed within the tumor have been detected by PCR in the plasma DNA of patients with various types of tumor (18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29) . The prognostic implications of circulating plasma DNA in patients with malignancies regarding the outcome of the disease are being examined. A correlation with poor survival in pancreatic carcinomas has been reported (30) , and two studies about the follow-up of lung cancer and melanoma patients have been published recently (31 , 32) . A novel plasma DNA utility has been used to screen somatic mutations that are frequent in tumors and detect them in a preclinical phase of the disease (33) .

The presence of microsatellite alterations in plasma DNA of bladder cancer patients has been reported recently (34 , 35) . The present study aims to: (a) detect tumor DNA at diagnosis in the plasma of such patients; and (b) analyze the distribution of various clinicopathological parameters. We characterized tumor DNA in plasma by checking alterations in microsatellite markers at described deleted loci, in tumor suppressor genes, and in the K-ras oncogene. To our knowledge, this is the first analysis of p14ARF promoter status in bladder cancer.

Materials and Methods

Tissue Sampling and DNA Extraction.

Between April 1999 and June 2001, 27 samples from tumor tissue were obtained immediately after TUR3 from patients with a diagnosis of bladder cancer (26 transitional cell carcinomas and 1 squamous tumor). They were then snap-frozen in liquid nitrogen and stored until processing. All of the specimens underwent histological examination (a) to confirm the diagnosis; (b) to confirm the presence of tumor and evaluate the percentage of tumor cells in each sample; and (c) to perform pathological staging. All of the samples showed at least 75% tumor cells. A blood sample was collected from each patient on the day of surgery before the TUR to avoid the possible clearance of plasma DNA after removal of the primary tumor. DNA was extracted from tumor tissues, normal blood cells, and plasma immediately. DNA was extracted from tumor tissue samples and peripheral blood mononuclear cells by a nonorganic method (5–4520 kit; Oncor, Gaithersburg, MD). Plasma DNA was purified on Qiagen columns (Quiamp Blood kit; Qiagen, Hilden, Germany) following the protocol for blood and body fluids, modified as described elsewhere (26) .

Analysis of Clinicopathological Parameters.

The following information was obtained from the medical records of the 27 patients: (a) birth and diagnosis dates; (b) radiological lymph node enlargement; (c) presence of multicentric disease; (d) tumor size; (e) histological subtype; (f) histological grade; (g) invasiveness; (h) pathological stage; (i) treatment; and (j) recurrences. All of the tumors were graded according to the number of mitotic elements and atypias. Pathological stage was classified by the Tumor-Node-Metastasis system, where T is the invasiveness of the tumor, N the lymph nodes affected, and M the metastases to other organs. All of the patients underwent TUR, and after staging, 9 patients were followed without any adjuvant treatment, 15 received intravesical therapy based on bacillus Calmette-Guérin, and 3 underwent radical cystectomy for invasion or progression of bladder cancer.

Microsatellite Analysis and PCR Conditions.

PCR was performed in a 10-μl reaction volume containing 50 ng/μl of sample DNA (tumor, mononuclear blood cells, or plasma DNA), 0.2 units of AmpliTaq Gold DNA polymerase (Perkin-Elmer, Roche Molecular Systems, Inc., Branchburg, NJ), 1 μl of 10 × PCR buffer [100 mm Tris-HCl, (pH 8.3), 500 mm KCl] 200 μm dNTP, 0.6 μm of each primer, and a range of concentrations of KCl and MgCl2 depending on the polymorphic marker. A 30-cycle amplification was carried out in a thermal cycler (Perkin-Elmer, Cetus, Foster City, CA). Six microsatellite markers were used to determine LOH on the following chromosomes: (a) 17: D17S695 (36) and D17S654 (37) ; (b) 13: D13S310 (38) ; (c) 11: TH2 (39) ; and (d) 9: D9S747 (accession no. GDB 335542) and D9S161 (40) . Annealing was at 63°C, 65°C, 56°C, 58°C, 63°C, and 60°C, respectively. The alleles were separated by mixing the 10 μl of the PCR products with 10 μl of loading buffer (0.02% xylene cyanol and 0.02% bromphenol blue). Electrophoresis was run on nondenaturing 8% polyacrylamide gels for 3–5 h at 500 V at room temperature. The allelic band intensity was then detected by silver staining and analyzed by densitometry. The gel image was captured using a GS-690 Imaging Densitometer (Bio-Rad Laboratories, Hercules, CA), digitalized in 400 dpi, and analyzed using Multi-Analyst/PC (Bio-Rad Laboratories). LOH was accepted when the signal of the allele was >75% lower than that observed in the normal counterpart DNA, considering that variations in the amplification process and especially the presence of small amounts of normal cells in the tumor tissue or, in our study, of normal blood cell DNA in plasma DNA, could lead to the expression of various band intensities in the total absence of one allele.

Mutational Study of the p53 Gene.

To detect point mutations in the conserved exons of p53, PCR-SSCP was performed as described elsewhere (26) . PCR was carried out in a final volume of 10 μl containing 50 ng of DNA template, 1 μl of 10 × PCR buffer, 0.2 units of AmpliTaq Gold DNA polymerase (Perkin-Elmer, Roche Molecular Systems, Inc.), 200 μm dNTP, 0.6 μm of each primer, and a range of concentrations of KCl and MgCl2 depending on the exon amplified. For PCR amplifications, the samples underwent 30 cycles. The amplified products were denatured by adding 10 μl of denaturing stop solution, which contained 98% formamide, 10 ml/liter edathamil (pH 8.0), 0.02% xylene cyanol, and 0.02% bromphenol blue, heated to 95°C for 5 min and rapidly cooled on ice. Electrophoresis was run on nondenaturing 10% polyacrylamide gels for 12–15 h at 250 v. The allelic band intensity on the gels was detected as described above. The specimens that showed a differential band at SSCP were amplified to obtain templates for DNA sequencing. These amplifications were independent of those used for SSCP analysis. Amplified DNA fragments were purified from 0.9% agarose gels using the Geneclean kit (Bio-101 Inc., La Jolla, CA) and sequenced using an ABI Prim 377 DNA apparatus (PE Applied Biosystems).

Mutational Study of the K-ras Oncogene.

PCR amplification of the K-ras gene, using 50 ng of DNA as template, was carried out in a 10 μl reaction volume with a final concentration of 1 × PCR buffer and 0.2 units of AmpliTaq Gold DNA polymerase (Perkin-Elmer, Roche Molecular Systems, Inc.), 200 μm dNTP mix, 0.6 of each primer, 2.5 mm MgCl2, and distilled H2O to reach the total volumes. Each sample was denatured at 94°C for 5 min and subjected to 30 cycles (94°C for 30 s, 58°C for 40 s, and 72°C for 30 s), followed by a final 7-min extension at 72°C. The amplified products were mixed with 10 μl of denaturing stop solution (see “Mutational study of the p53 gene”), heated to 95°C for 5 min, and rapidly cooled on ice. The samples were electrophoresed on nondenaturing 12% polyacrylamide gels at 250 v overnight at 4°C. Products were visualized by nonradioisotopic means. The primers used for amplification of exon 1 of K-ras, which contains codons 12 and 13, were: 5′GACTGAATATAAACTTGTGGTAGT and 5′CTATTGTTGGATCATATTCGTCC. All of the specimens showing a differential band at SSCP were sequenced following the method used for the p53 gene.

Promoter Hypermethylation.

p16INK4a and p14ARF aberrant promoter methylation was analyzed in tumor, mononuclear blood cells, and plasma DNA. DNA methylation patterns in the CpG island of the p16INK4a and p14ARF genes were determined by methylation-specific PCR as described elsewhere (41) . Briefly, 1 μg of DNA from tumor, blood cells, and plasma was denatured by NaOH, and subsequently treated with hydroquinone and sodium bisulfite at 53°C for 16 h. Modified DNA samples were purified using the Wizard DNA purification resin following the manufacturer instructions (Promega) and eluted into 50 μl of water. NaOH was added to complete the modification followed by ethanol precipitation. Resuspended DNA was used in a PCR reaction. Primer sequences and PCR conditions for p16INK4a and p14ARF are reported elsewhere (41 , 42) . Placental DNA treated with SssI methyltransferase and DNA of Raji, KMH2, and l-540 cell lines were used as positive controls for methylated alleles. DNA from normal lymphocytes was used as a negative control for methylated genes. Samples were electrophoresed on nondenaturing 8% gels at 450 v for 2–3 h and visualized by nonradioisotopic techniques.

Statistical Analysis.

The variables were contrasted using the χ2 test. Differences are considered significant where P < 0.05. Statistical analyses were performed using the EPI-INFO package, version 6.04.

Results

Microsatellite Analysis.

Fifteen bladder carcinoma patients (56%) showed allelic loss in at least one locus. Nine of these (60%) had the same microsatellite alteration in their plasma DNA. The marker D9S161 showed the highest individual rate of LOH in tumor DNA (30%), but D9S747 showed the highest correlation between tumor and plasma DNA (100%; Fig. 1A⇓ ). In 6 cases, plasma DNA revealed an additional alteration, which was not present in tumor DNA (Fig. 1B)⇓ , although 3 of these cases showed LOH in their tumor and plasma samples for some of the other microsatellite markers.

Fig. 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 1.

Photograph showing: A, LOH in the D9S747 microsatellite in tumor and plasma DNA. B, LOH in the D17S654 marker in plasma DNA but not found in tumor DNA. C, p53 mutation in tumor but not in plasma DNA. D, K-ras mutation in both tumor and plasma DNA. E, p14ARF promoter hypermethylation in tumor and plasma DNA. F, p16INK4a promoter hypermethylation in tumor and plasma DNA. W, water blanks as negative controls; N, normal mononuclear blood cells DNA; T, tumor DNA; P, plasma DNA; +, positive controls, KMH2 cell line for p14ARF methylation and Raji cell line for p16INK4a methylation.

p53 Gene Mutations.

Only 1 tumor patient showed a mutation in exon 8 of p53, which was not found in the corresponding plasma sample (Fig. 1C)⇓ . Another patient presented a nucleotide change in exon 6 of p53 in both normal blood cells and tumor DNA, but again, it was not detected in plasma. The incidence of p53 mutations was lower (3.7%) than in other studies (43 , 44) , but in a recent report, 1% of p53 mutations were detected by microarray technology (45) .

K-ras Gene Mutations.

In 2 cases, the same K-ras mutations were identified in both tumor tissue and plasma (Fig. 1D)⇓ . One case showed de novo K-ras mutation in plasma, which was not detected in its tumor counterpart. This case showed LOH for D9S747 and D13S310 microsatellite markers in the tumor and plasma samples. Mutations in the K-ras oncogene are rare in human bladder cancers (46) .

Methylation Status of the p14ARF and p16INK4a Promoters.

Methylation of 5′ regulatory regions of CG dinucleotides, called CpG islands, is a well-established mechanism of transcriptional repression (47) . p14ARF and p16INK4a are candidates for hypermethylation-associated inactivation, because they contain documented CpG islands that can be silenced by this epigenetic alteration in many tumor types (48, 49, 50) . Of the bladder tumor samples amplified, 15 (56%) and 5 (18%) presented p14ARF and p16INK4a promoter hypermethylation, respectively. Of these, 13 (87%) and 2 (40%) showed p14ARF and p16INK4a promoter hypermethylation in plasma samples, respectively (Fig. 1, E and F)⇓ . All of the cases with p16INK4a promoter hypermethylation were positive for p14ARF promoter hypermethylation. Bisulfite-modified DNA from the 27 normal blood cells samples was not amplified with either primers. To our knowledge, p14ARF promoter hypermethylation has not been analyzed in bladder cancer patients and we cannot compare our results. However, the percentage found for p16INK4a promoter hypermethylation is within reported ranges for bladder carcinomas (51 , 52) .

Correlations between Clinicopathological Parameters and Molecular Changes.

Of the 27 patients, 21 (78%) showed in the tumor sample at least one of the alterations analyzed. A significant correlation was found between tumor p14ARF promoter hypermethylation and multicentric foci (P = 0.04), tumor size (P = 0.006), bladder muscle invasion (P = 0.01), and stage (P = 0.01). Nearly statistically significant was lymph nodes enlargement (P = 0.05; Table 1⇓ ). No statistical associations were found in regard to LOH in the tumor samples.

View this table:
  • View inline
  • View popup
Table 1

Methylation status of bladder tumors

Statistical associations between bladder cancer cases with tumor DNA p14ARF promoter hypermethylation and tumor samples that do not show this alteration in regard to various clinicopathological parameters.

Twenty cases (74%) showed at least one of the alterations in plasma DNA (17 cases displayed the same alterations in their tumor and plasma samples, and 3 cases showed LOH in plasma but not in their tumor samples for any of the microsatellites analyzed). There was a significant association between p14ARF hypermethylation in plasma DNA and multicentric foci (P = 0.03), larger tumors (P = 0.01), and relapse (P = 0.03). Close to statistical significance (P = 0.05) were lymph node enlargement (the only 3 patients harboring positive nodes showed promoter hypermethylation), invasion of the bladder muscle, more advanced stages, and the treatment applied; the 3 patients subjected to more aggressive therapy, i.e., cystectomy, showed p14ARF promoter hypermethylation in their plasma DNA (Table 2)⇓ . A statistical association between plasma LOH in at least one of the markers analyzed and recurrence of the disease was detected (P = 0.02; Table 2⇓ ).

View this table:
  • View inline
  • View popup
Table 2

Methylation status of tumor plasma DNA

Statistical associations between bladder cancer cases with DNA plasma alterations (p14ARF promoter hypermethylation or microsatellite changes) and cases with no alterations regarding various clinicopathological parameters.

The association with the clinical parameters was not analyzed for p53 and K-ras mutations, and p16INK4a aberrant methylation because of the very low number of cases showing these alterations, which could lead to misinterpretation results.

Discussion

This is the first study to identify a possible indicator of disease recurrence for bladder cancer in plasma DNA.

Twenty-six transitional cell carcinomas and 1 squamous tumor, and their corresponding mononuclear blood cells and plasma samples were analyzed for DNA microsatellite alterations, p53 and K-ras mutations, and p14ARF/p16INK4a promoter hypermethylation. Seventeen cases showed the same alteration in plasma and tumor DNA, indicating that this plasma DNA derives from the primary tumor. Six cases presented a new alteration in plasma, which was not found in the tumor counterpart. Most studies on plasma DNA reveal a few alterations in plasma only, mainly when microsatellite polymorphic markers are used to characterize tumor and plasma DNA (22 , 26) . Some authors suggest that plasma alterations could be artifacts (27 , 28) , although they are not detected in healthy controls (26 , 35) . Other authors point to a heterogeneous clonal origin (22 , 24) . The common multiple foci found in bladder cancer patients may have a monoclonal origin, which is followed by cellular spreading (8, 9, 10) . Once the microfoci have migrated, they may evolve and acquire new alterations. In this case, the specific alterations in plasma DNA but not in the tumor sample could be explained by the fact that this DNA proceeds from other tumor foci which harbor the alteration, as we have described recently for colon carcinomas (53) .

The low proportion of p53 and K-ras mutations, and p16INK4a hypermethylation in our series of bladder cancer samples indicates that they are not suitable markers. Nevertheless, microsatellite alterations or p14ARF promoter hypermethylation was detected in 56% of tumors, but concordance between tumor and plasma alterations was higher for p14ARF status (87% versus 60%). p14ARF promoter hypermethylation has been reported in other tumors, such as colorectal (42) , gastric (54) , breast (55) , ovarian (56) , oral squamous cell carcinomas (57) , oligodendrogliomas (58) , glioblastomas (59) , and central nervous system lymphomas (60) .

It is remarkable that recurrence was associated with p14ARF promoter hypermethylation or LOH only when the alteration was present in plasma. This observation could be because of the specificity to find alterations in the plasma sample. Because of the multicentric foci in bladder cancer, we could have a tumoral sample from a focus not showing the alteration observed in the plasma. Thus, the case would be classified inaccurately as without alteration, which could modify the results.

Although alterations in plasma, LOH, and p14ARF promoter aberrant methylation could predict relapse, p14ARF promoter hypermethylation is a better prognosis marker for several reasons. Firstly, although in our subset of bladder cancer patients the proportion of these alterations in the tumors was identical (56%), concordance between presence in tumor and plasma DNA was higher for p14ARF aberrant promoter methylation. Secondly, for microsatellite analysis, some of these markers should be tested to obtain an acceptable rate of LOH. To check the promoter status of a gene, only one reaction is required.

Improvements in molecular and genetic approaches have led to the identification of tumor-derived nucleic acids in the plasma of cancer patients (20, 21, 22 , 24 , 26 , 27 , 31 , 32 , 37 , 61 , 62) , although the mechanisms by which these nucleic acids are released into plasma remain unknown (62, 63, 64, 65) . It is suggested that the alterations found in the plasma DNA of these patients could be used as a prognostic factor. We have detected plasma DNA with tumor features in a series of 27 bladder cancer patients. p14ARF promoter hypermethylation may be a useful prognostic factor, because it could be associated with recurrence disease and could be clinically relevant as a noninvasive tool for the detection of relapses during the follow-up of patients.

Acknowledgments

We thank the patients who participated in this study and Robin Rycroft for his assistance with the English manuscript.

Footnotes

  • The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

  • ↵1 Supported by grants from FIS No. 01/0505, SAF 2001-0004, and Bristol-Myers, S. A.

  • ↵2 To whom requests for reprints should be addressed, at Department of Medical Oncology, Molecular Genetics Unit, Clínica Puerta de Hierro, C/San Martin de Porres 4, E-28035 Madrid, Spain. Phone: 34-91-386-6527; Fax: 34-91-373-7667; E-mail: felixbv{at}stnet.es

  • ↵3 The abbreviations used are: TUR, transurethral resection; dNTP, deoxynucleotide triphosphate; LOH, loss of heterozygosity; SSCP, single-strand conformational polymorphism.

  • Received October 30, 2001.
  • Revision received January 8, 2002.
  • Accepted January 28, 2002.

References

  1. ↵
    Parker S. L., Tong T., Bolden S., Wingo P. A. Cancer statistics 1996. CA Cancer J. Clin., 46: 5-27, 1996.
    OpenUrlCrossRefPubMed
  2. ↵
    Zang Z. F., Sarkis A. S., Cordón-Cardó C., Dalbagni G., Melamed J., Aprikian A., Pollack D., Shienfeld J., Herr H. W. Tobacco smoking, occupation, and p53 overexpression in early stage bladder cancer. Cancer Epidemiol. Biomark. Prev., 3: 19-24, 1994.
    OpenUrlAbstract
  3. ↵
    Fair, W. R., Fuks, Z. Y., and Scher, H. I. Cancer of the bladder. In: V. DeVita, Jr., S. Hellman, and S. A. Rosenberg (eds.), Cancer: Principles & Practice of Oncology, pp.1052–1072. Philadelphia: JB. Lippincott. 1994.
  4. ↵
    Wolf H., Kakizoe T., Smith P. H., Brosman S. A., Okajima E., Rubben H., Utz D. C. Bladder tumors. Treated natural history. Prog. Clin. Biol. Res., 221: 223-255, 1986.
    OpenUrlPubMed
  5. ↵
    Raghavan D., Shipley W., Garnick M., Russel P., Richie J. Biology and management of bladder cancer. N. Engl. J. Med., 322: 1129-1138, 1990.
    OpenUrlCrossRefPubMed
  6. ↵
    Catalona W. J. Urothelial tumors of the urinary tract Walsh P. C. Retik A. B. Stanley T. A. Vaughan E. D., Jr eds. . Campbell’s Urology, 1094-1158, WB Saunders Co. Philadelphia 1992.
  7. ↵
    Whitmore W. F., Jr Toward the rational management of bladder cancer: an overview. Urology, 31: 5-8, 1998.
  8. ↵
    Sidransky D., Frost P., von Eschenbach A., Oyasu R., Preisinger A. C., Vogelstein B. Clonal origin of bladder cancer. N. Engl. J. Med., 326: 737-740, 1992.
    OpenUrlCrossRefPubMed
  9. ↵
    Mao L., Lee D. J., Tockman M. S., Erozan Y. S., Askin F., Sidransky D. Microsatellite alterations as clonal markers for the detection of human cancers. Proc. Natl. Acad. Sci. USA, 91: 9871-9875, 1994.
    OpenUrlAbstract/FREE Full Text
  10. ↵
    Habuchi T., Takahashi R., Yamada H., Kakehi Y., Sugiyama T., Yoshida O. Metachronous multifocal development of urothelial cancers by intraluminal seeding. Lancet, 342: 1087-1088, 1993.
    OpenUrlCrossRefPubMed
  11. ↵
    Richter J., Beffa L., Wagner U., Schrmal P., Gasser T., Moch H., Mihatsch M., Sauter G. Patterns of chromosomal imbalances in advanced urinary bladder cancer detected by comparative genomic hybridization. Am. J. Pathol., 153: 1615-1621, 1998.
    OpenUrlCrossRefPubMed
  12. ↵
    Simon R., Bürger H., Brinkschmidt C., Böcker W., Hertle L., Terpe H. Chromosomal aberrations associated with invasion in papillary superficial bladder cancer. J. Pathol., 185: 345-351, 1998.
    OpenUrlCrossRefPubMed
  13. ↵
    Voorter C., Joos S., Bringuier P. P., Vallinga M., Poddighe P., Schalken J., du Manoir S., Ramaekers F., Lichter P., Hopman A. Detection of chromosomal imbalances in transitional cell carcinoma of the bladder by comparative genomic hybridization. Am. J. Pathol., 146: 1341-1354, 1995.
    OpenUrlPubMed
  14. ↵
    Knowles M. A., Elder P. A., Williamson M., Cairns J. P., Shaw M. E., Law M. G. Allelotype of human bladder cancer. Cancer Res., 54: 531-538, 1994.
    OpenUrlAbstract/FREE Full Text
  15. ↵
    Kallioniemi A., Kallioniemi O., Citro G., Sauter G., DeVries S., Kerschmann R., Caroll P., Waldman F. Identification of novel DNA amplifications and deletions in primary bladder cancer by comparative genomic hybridization. Gene Chromosome Cancer, 12: 213-219, 1995.
    OpenUrlCrossRefPubMed
  16. ↵
    Shapiro B., Chakrabarty M., Cohn E. M., Leon S. A. Determination of circulating DNA levels in patients with benign or malignant gastrointestinal disease. Cancer (Phila.), 51: 2116-2120, 1983.
    OpenUrlCrossRefPubMed
  17. ↵
    Leon S. A., Shapiro B., Sklaroff D. M., Yaros J. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res., 37: 646-650, 1997.
    OpenUrlAbstract/FREE Full Text
  18. ↵
    Mulcahy H. E., Lyautey J., Lederrey C., Cheng X. Q., Anker P., Alstead E. M., Ballinger A., Farthing M. J., Stroun M. A prospective study of K-ras mutations in the plasma of pancreatic cancer patients. Clin. Cancer Res., 4: 271-275, 1998.
    OpenUrlAbstract/FREE Full Text
  19. ↵
    Vasioukhin V., Anker P., Maurice P., Lyautey J., Lederrey C., Stroun M. Point mutation of the N-ras gene in the blood plasma DNA of patients with myelodysplastic syndrome or acute myelogenous leukaemia. Br. J. Haematol., 86: 774-779, 1994.
    OpenUrlCrossRefPubMed
  20. ↵
    Silva J. M., Gonzalez R., Dominguez G., Garcia J. M., España P., Bonilla F. TP53 gene mutations in plasma DNA of cancer patients. Gene Chromosome Cancer, 24: 160-161, 1999.
    OpenUrlCrossRefPubMed
  21. ↵
    Nawroz H., Koch W., Anker P., Stroun M., Sidransky D. Microsatellite alterations in serum DNA of head and neck cancer patients. Nat. Med., 2: 1035-1037, 1996.
    OpenUrlCrossRefPubMed
  22. ↵
    Goessl C., Heicapell R., Münker R., Anker P., Stroun M., Krause H., Müllr M., Miller K. Microsatellite analysis of plasma DNA from patients with clear cell renal carcinoma. Cancer Res., 58: 4728-4732, 1998.
    OpenUrlAbstract/FREE Full Text
  23. ↵
    Wong I. H. N., Lo D., Zhang J., Liew C. T., Ng L., Wong N., Lai S., Lau Y., Hjelm M., Johnson P. J. Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients. Cancer Res., 59: 71-73, 1999.
    OpenUrlAbstract/FREE Full Text
  24. ↵
    Chen X. Q., Stroun M., Magnenat J. L., Nicod L. P., Kurt A. M., Lyautey J., Lederrey C., Anker P. Microsatellite alterations in plasma DNA of small cell lung cancer patients. Nat. Med., 2: 1033-1035, 1996.
    OpenUrlCrossRefPubMed
  25. ↵
    Esteller M., Sanchez-Cespedes M., Rosell R., Sidransky D., Baylin S. B., Herman J. G. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res., 59: 67-70, 1999.
    OpenUrlAbstract/FREE Full Text
  26. ↵
    Silva J. M., Dominguez G., Garcia J. M., Gonzalez R., Villanueva M. J., Navarro F., Provencio M., San Martin S., España P., Bonilla F. Presence of tumor DNA in plasma of breast cancer patients: clinicopathological correlations. Cancer Res., 59: 3251-3256, 1999.
    OpenUrlAbstract/FREE Full Text
  27. ↵
    Chen X., Bonnefoi H., Diebol-Berger S., Lyautey J., Lederrey C., Faltin-Traub E., Stroun M., Anker P. Detecting of tumor-related alterations in plasma or serum DNA of patients diagnosed with breast cancer. Clin. Cancer Res., 5: 2297-2303, 1999.
    OpenUrlAbstract/FREE Full Text
  28. ↵
    Mayall F., Fairweather S., Wilkins R., Chang B., Nicholls R. Microsatellite abnormalities in plasma of patients with breast carcinoma: concordance with the primary tumor. J. Clin. Pathol., 52: 363-366, 1999.
    OpenUrlAbstract
  29. ↵
    Anker P., Lefort F., Vasioukhin V., Lyautey J., Lederrey C., Chen X. Q., Stroun M., Mulcahy H. E., Farthing M. J. K-ras mutations are found in DNA extracted from the plasma of patients with colorectal cancer. Gastroenterology, 112: 1114-1120, 1997.
    OpenUrlCrossRefPubMed
  30. ↵
    Castells A., Puig P., Mora J., Boadas J., Boix L., Urgell E., Sole M., Capella G., Lluis F., Fernandez-Cruz L., Navarro S., Farre A. K-ras mutations in DNA extracted from the plasma of patients with pancreatic carcinoma: diagnostic utility and prognostic significance. J. Clin. Oncol., 17: 578-584, 1999.
    OpenUrlAbstract/FREE Full Text
  31. ↵
    Sozzi G., Conte D., Mariani L., Lo Vullo S., Roz L., Lombardo C., Pierotti M., Tavecchio L. Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients. Cancer Res., 61: 4675-4678, 2001.
    OpenUrlAbstract/FREE Full Text
  32. ↵
    Taback B., Fujiwara Y., Wang H-J., Foshag L. J., Morton D. L., Hoon D. S. B. Prognostic significance of circulating microsatellite markers in the plasma of melanoma patients. Cancer Res., 61: 5723-5726, 2001.
    OpenUrlAbstract/FREE Full Text
  33. ↵
    Kopreski M. S., Benko F. A., Borys D. J., Khan A., McGarrity T. J., Gocke C. D. Somatic mutations screening: identification of individuals harboring K-ras mutations with the use of plasma DNA. J. Natl. Cancer Inst., 92: 918-923, 2000.
    OpenUrlAbstract/FREE Full Text
  34. ↵
    Utting M., Werner W., Muller G., Schubert J., Junker K. A possible noninvasive method for the detection of bladder cancer in patients: microsatellite analysis of free DNA in urine and blood. Ann N. Y. Acad Sci., 945: 31-35, 2001.
    OpenUrlCrossRefPubMed
  35. ↵
    Von Knobloch R., Hegele A., Brandt H., Olbert P., Heidenreich A., Hofmann R. Serum DNA and urine DNA alterations of urinary transitional cell bladder carcinoma detected by fluorescent microsatellite analysis. Int. J. Cancer, 94: 67-72, 2001.
    OpenUrlCrossRefPubMed
  36. ↵
    Gerken S. C., Albertsen H., Elsner T., Ballard L., Holik P., Lawrence E., Moore M., Zhao X., White R. A strategy for constructing high-resolution genetic maps of the human genome: a genetic map of chromosome 17p, ordered with meiotic breakpoint-mapping panels. Am. J. Hum. Genet., 56: 484-499, 1995.
    OpenUrlPubMed
  37. ↵
    Steiner G., Schoenberg M. P., Linn J. F., Mao L., Sidransky D. Detection of bladder cancer recurrence by microsatellite analysis of urine. Nat. Med., 3: 621-624, 1997.
    OpenUrlCrossRefPubMed
  38. ↵
    Silva J. M., Gonzalez R., Provencio M., Dominguez G., Garcia J. M., Gallego I., Palacios J., España P., Bonilla F. Loss of heterozygosity in BRCA1 and BRCA2 markers and high-grade malignancy in breast cancer. Breast Cancer Res. Treat., 53: 9-17, 1999.
    OpenUrlCrossRefPubMed
  39. ↵
    Deng G., Lu Y., Zlotnikov G., Thor A. N., Smith H. S. Loss of heterozygosity in normal tissue adjacent to breast carcinomas. Science (Wash. DC), 274: 2057-2059, 1996.
    OpenUrlAbstract/FREE Full Text
  40. ↵
    Brenner A. J., Aldaz C. M. Chromosome 9p allelic loss and p16/CDKN2 in breast cancer and evidence of p16 inactivation in immortal breast epithelial cells. Cancer Res., 55: 2892-2895, 1995.
    OpenUrlAbstract/FREE Full Text
  41. ↵
    Herman J. G., Graff J. R., Myöhänen S., Nelkin B. D., Baylin S. B. Methylation-specific PCR. a novel PCR assay for methylation status of CpG islands. Proc. Natl. Acad. Sci. USA, 93: 9821-9826, 1996.
    OpenUrlAbstract/FREE Full Text
  42. ↵
    Esteller M., Tortola S., Toyota M., Capella G., Peinado M. A., Baylin S. B., Herman J. G. Hypermethylation-associated inactivation of p14ARF is independent of p16INK4a methylation and p53 mutational status. Cancer Res., 60: 129-133, 2000.
    OpenUrlAbstract/FREE Full Text
  43. ↵
    Masuda A., Kikuchi Y. Y., Kawamura N. Mutational analysis of the p53 tumor suppressor gene using paraffin-embedded specimens of human transitional cell carcinomas by the direct sequencing method. Tokai J. Exp. Clin. Med., 25: 69-77, 2000.
    OpenUrlPubMed
  44. ↵
    Berggren P., Steineck G., Adolfsson J., Hansson J., Jansson O., Larsson O., Larsson P., Sandstedt B., Wijkstrom H., Hemminki K. p53 mutations in urinary bladder cancer. Br. J. Cancer., 84: 1505-1511, 2001.
    OpenUrlCrossRefPubMed
  45. ↵
    Wikman F. P., Lu M. L., Thykjaer T., Olesen S. H., Andersen L. D., Cordon-Cardo C., Ornto T. J. Evaluation of the performance of a p53 sequencing microarray chip using 140 previously sequenced bladder tumor samples. Clin Chem., 46: 1555-1561, 2000.
    OpenUrlAbstract/FREE Full Text
  46. ↵
    Przybojewska B., Jagiello A., Jalmuzna P. H-ras. K-ras and N-ras gene activation in human bladder cancers. Cancer Genet. Cytogenet., 121: 73-77, 2000.
    OpenUrlCrossRefPubMed
  47. ↵
    Bird A. The essential of the DNA methylation. Cell, 70: 5-8, 1992.
    OpenUrlCrossRefPubMed
  48. ↵
    Gonzalez-Zulueta M., Bender C. M., Yang A. S., Nguyen T., Beart R. W., Van Tornout J. M., Jones P. A. Methylation of the 5′ CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res., 55: 4531-4535, 1995.
    OpenUrlAbstract/FREE Full Text
  49. ↵
    Merlo A., Herman J. G., Mao L., Lee D. J., Gabrielson E., Burger P. C., Baylin S. B., Sidransky D. 5′ CpG island methylation is associated with transcriptional silencing of the tumor suppressor CDKN2/p16 in human cancers. Nat. Med., 7: 686-692, 1995.
  50. ↵
    Robertson, K. D., and Jones, P. A. The human ARF cell cycle regulatory gene promoter is a CpG island which can be silenced by DNA methylation and downregulated by wildtype p53. Mol. Cell Biol., 18: 6457–6473, 1998.ç.
  51. ↵
    Tsutsumi M., Tsai Y. C., Gonzalgo M. L., Nichols P. W., Jones P. A. Early acquisition of homozygous deletions of p16/p19 during squamous cell carcinogenesis and genetic mosaicism in bladder cancer. Oncogene, 17: 3021-3027, 1998.
    OpenUrlCrossRefPubMed
  52. ↵
    Orlow I., LaRue H., Osman I., Lacombe L., Moore L., Rabbani F., Meyer F., Fradet Y., Cordon-Cardo C. Deletions of the INK4A gene in superficial bladder tumors. Association with recurrence. Am. J. Pathol., 155: 105-113, 1999.
    OpenUrlPubMed
  53. ↵
    Garcia J. M., Silva J. M., Dominguez G., Silva J., Bonilla F. Heterogeneous tumor clones as an explanation of discordance between plasma DNA and tumor DNA alterations. Genes Chromosome Cancer, 31: 300-301, 2001.
    OpenUrlCrossRefPubMed
  54. ↵
    Iida S., Akiyama Y., Nakajima T., Ichikawa W., Nihei Z., Sugihara K., Yuasa Y. Alterations and hypermethylation of the p14(ARF) gene in gastric cancer. Int. J. Cancer, 87: 654-658, 2000.
    OpenUrlCrossRefPubMed
  55. ↵
    Silva J., Dominguez G., Silva J. M., Garcia J. M., Gallego I., Corbacho C., Provencio M., España P., Bonilla F. Analysis of genetic and epigenetic processes that influence p14ARF expression in breast cancer. Oncogene, 20: 4586-4590, 2001.
    OpenUrlCrossRefPubMed
  56. ↵
    Hashiguchi Y., Tsuda H., Yamamoto K., Inoue T., Ishiko O., Ogita S. Combined analysis of p53 and RB pathways in epithelial ovarian cancer. Hum. Pathol., 32: 988-996, 2001.
    OpenUrlCrossRefPubMed
  57. ↵
    Shintani S., Nakahara Y., Mihara M., Ueyama Y., Matsumura T. Inactivation of the p14(ARF), p15(INK4B) and p16(INK4A) genes is a frequent event in human oral squamous cell carcinomas. Oral Oncol., 37: 498-504, 2001.
    OpenUrlCrossRefPubMed
  58. ↵
    Watanabe T., Nakamura M., Yonekawa Y., Kleihues P., Ohgaki H. Promoter hypermethylation and homozygous deletion of the p14ARF and p16INK4a genes in oligodendrogliomas. Acta Neuropathol., 101: 185-189, 2000.
    OpenUrl
  59. ↵
    Nakamura M., Watanabe T., Klangby U., Asker C., Wiman K., Yonekawa Y., Kleihues P., Ohgaki H. p14ARF deletion and methylation in genetic pathways to glioblastomas. Brain Pathol., 11: 159-168, 2001.
    OpenUrlPubMed
  60. ↵
    Nakamura M., Sakaki T., Hashimoto H., Nakase H., Ishida E., Shimada K., Konishi N. Frequent alterations of the p14(ARF) and p16(INK4a) genes in primary central nervous system lymphomas. Cancer Res., 61: 6335-6339, 2001.
    OpenUrlAbstract/FREE Full Text
  61. ↵
    Fujiwara Y., Chi D. D., Wang H., Keleman P., Morton D. L., Turner R., Honn D. S. Plasma DNA microsatellite as tumor-specific markers and indicators of tumor progression in melanoma patients. Cancer Res., 59: 1567-1571, 1999.
    OpenUrlAbstract/FREE Full Text
  62. ↵
    Lo Y. M., Chan L. Y., Lo K. W., Leung S. F., Zhang J., Chan A. T., Lee J. C., Hjelm N. H., Johnson P. S., Huang D. P. Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res., 59: 1188-1191, 1999.
    OpenUrlAbstract/FREE Full Text
  63. ↵
    Fournie G. J., Courtin J. P., Laval F., Chale J. J., Pourrat J. P., Pujazon M. C., Lauque D., Carles P. Plasma DNA as a marker of cancerous cell death. Investigations in patients suffering from lung cancer and in nude mice bearing human tumors. Cancer Lett., 91: 221-227, 1995.
    OpenUrlCrossRefPubMed
  64. ↵
    Rogers J. C., Boldt D., Kornfeld S., Skinner A., Valeri C. R. Excretion of deoxyribonucleic acid by lymphocytes stimulated with phytohemagglutinin or antigen. Proc. Natl. Acad. Sci. USA, 69: 1685-1689, 1972.
    OpenUrlAbstract/FREE Full Text
  65. ↵
    Anker P., Mulcahy H., Chen X. Q., Stroun M. Detection of circulating tumor DNA in the blood (plasma/serum) of cancer patients. Cancer Metastasis Rev., 18: 65-73, 1999.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top
April 2002
Volume 8, Issue 4
  • Table of Contents

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Clinical Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
p14ARF Promoter Hypermethylation in Plasma DNA as an Indicator of Disease Recurrence in Bladder Cancer Patients
(Your Name) has forwarded a page to you from Clinical Cancer Research
(Your Name) thought you would be interested in this article in Clinical Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
p14ARF Promoter Hypermethylation in Plasma DNA as an Indicator of Disease Recurrence in Bladder Cancer Patients
Gemma Domínguez, Joaquín Carballido, Javier Silva, Jose M. Silva, Jose M. García, Josefa Menéndez, Mariano Provencio, Pilar España and Felix Bonilla
Clin Cancer Res April 1 2002 (8) (4) 980-985;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
p14ARF Promoter Hypermethylation in Plasma DNA as an Indicator of Disease Recurrence in Bladder Cancer Patients
Gemma Domínguez, Joaquín Carballido, Javier Silva, Jose M. Silva, Jose M. García, Josefa Menéndez, Mariano Provencio, Pilar España and Felix Bonilla
Clin Cancer Res April 1 2002 (8) (4) 980-985;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • CpG Island Methylator Phenotype Is an Independent Predictor of Survival Benefit from 5-Fluorouracil in Stage III Colorectal Cancer
  • Haptoglobin-α Subunit As Potential Serum Biomarker in Ovarian Cancer
  • Prognostic Importance of Promoter Hypermethylation of Multiple Genes in Esophageal Adenocarcinoma
Show more Advances in Brief
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • CCR Focus Archive
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Clinical Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Clinical Cancer Research
eISSN: 1557-3265
ISSN: 1078-0432

Advertisement